Bicycle Therapeutics plc

DB:50BA Stock Report

Market Cap: €891.9m

Bicycle Therapeutics Future Growth

Future criteria checks 2/6

Bicycle Therapeutics is forecast to grow earnings and revenue by 19% and 52.4% per annum respectively. EPS is expected to grow by 22.4% per annum. Return on equity is forecast to be -48.1% in 3 years.

Key information

19.0%

Earnings growth rate

22.4%

EPS growth rate

Biotechs earnings growth32.3%
Revenue growth rate52.4%
Future return on equity-48.1%
Analyst coverage

Good

Last updated31 Jan 2025

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:50BA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027142-271-188-13210
12/31/202647-293-232-21412
12/31/202532-247-211-17713
12/31/202437-178-179-12913
9/30/202437-166-204-203N/A
6/30/202440-165-165-164N/A
3/31/202442-168-86-85N/A
12/31/202327-181-64-61N/A
9/30/202325-162-48-44N/A
6/30/202323-140-55-48N/A
3/31/202315-124-122-106N/A
12/31/202214-113-105-86N/A
9/30/202215-101-85-66N/A
6/30/202216-87-54-39N/A
3/31/202214-78-34-27N/A
12/31/202112-67-17-15N/A
9/30/202112-66-22-21N/A
6/30/202111-62-54-53N/A
3/31/202111-56-54-53N/A
12/31/202010-51-19-18N/A
9/30/202012-38-7-6N/A
6/30/20209-37-8-7N/A
3/31/20209-35-4-2N/A
12/31/201914-31-30-29N/A
9/30/201910-33-34-33N/A
6/30/201911-31-28-26N/A
3/31/201911-26-25-24N/A
12/31/20187-22-27-26N/A
9/30/20187-21-20-19N/A
12/31/20172-16N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 50BA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 50BA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 50BA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 50BA's revenue (52.4% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 50BA's revenue (52.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 50BA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 03:27
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bicycle Therapeutics plc is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Kalpit PatelB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity